Novartis India Limited: Business Overview, Financials & Competitive Analysis
Novartis India Limited scores 4/10 on the AskCyborg Cyborg Score (Mixed). Financially stable subsidiary with niche pharma positioning in India, but constrained by weak sales growth and modest returns on equity relative to peers. Novartis India demonstrates solid financial stability with low debt and decent profitability (₹93.2 Cr profit), but faces headwinds with declining revenue growth (-1.46% over 5 years).
What is Novartis India Limited's industry? Novartis India Limited (novartis.com) operates in Pharmaceuticals. AskCyborg classifies Novartis India Limited under Pharmaceuticals in its company registry.
Novartis India Limited is primarily engaged in the wholesale of pharmaceuticals and medical goods, with a focus on pain management, organ transplantation, and neuroscience. The company has a market capitalization of ₹...
Cyborg Score thesis
Financially stable subsidiary with niche pharma positioning in India, but constrained by weak sales growth and modest returns on...
Read the full analyst-debate transcript →Get the Latest Novartis India Limited Report
Up-to-date AI-powered research, analyst debate audio & saved-company playlists
Get Current Report FreeNovartis India Limited Overview
Pro stress-test →Novartis India Limited is primarily engaged in the wholesale of pharmaceuticals and medical goods, with a focus on pain management, organ transplantation, and neuroscience. The company has a market capitalization of ₹3,628 crore with annual revenue of ₹354 crore and profit of ₹93.2 crore. As a publicly listed subsidiary of global pharma giant Novartis, the company operates in the Indian pharmaceutical market through both imports and distribution of specialized medicines.
Strategic Profile
Pro stress-test →Novartis India has delivered poor sales growth of -1.46% over the past five years and shows a low return on equity of 11.9% over the last three years, indicating operational challenges in a competitive domestic market. With promoter holding at 70.7%, the company maintains strong parent control, and has reduced debt and is almost debt-free, providing financial stability despite growth headwinds. The company's therapeutic focus on specialized areas positions it as a niche player in the Indian pharmaceutical landscape.
Competitive Landscape
Pro stress-test →Novartis India competes with Alkem Laboratories, Sun Pharmaceutical Industries, Zydus Lifesciences, GSK, and Takeda Pharmaceutical in the Indian pharmaceutical market. These competitors span both branded specialty pharma and generics segments, creating pricing and margin pressure across the company's therapeutic focus areas.
Industry Context
Novartis India Limited operates in Pharmaceuticals.
Key facts
Founded: Not specified in sources · Headquarters: Hyderabad, India · Employees: Not disclosed · Revenue: ₹354 crore (FY2025) · Market cap: ₹3,628 crore (~$435M USD)